Đang chuẩn bị liên kết để tải về tài liệu:
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: Results of matching-adjusted indirect comparison analyses

In the absence of head-to-head trials comparing axitinib with cabozantinib or everolimus, the aim of this study was to conduct an indirect comparison of their relative efficacy in patients with metastatic renal cell carcinoma (mRCC), using data from the AXIS and METEOR trials. | Axitinib cabozantinib or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma Results of matching-adjusted indirect comparison analyses